INTRODUCTION

CD4
1 CD25 1 FoxP3 1 regulatory T cells (Treg) have an important role in the control of alloreactivity in allogeneic stem cells transplantation [1] . The first direct demonstration of Treg immunosuppressive effect on alloreactivity was made in experimental bone marrow (BM) transplantation (BMT) in mice, where complete Treg depletion before grafting significantly accelerated the mortality linked to graft-versus-host disease (GVHD) [2, 3] . These observations led to the study of Treg content in transplants as a predictive factor for GVHD in humans. However, despite increasing evidences that Treg content could have diagnostic and prognostic value for acute GVHD (aGVHD) when assessed in grafted patients [4] , clinical studies were never performed in BM transplants and remain controversial in peripheral blood stem cell (PBSC) transplants (for review, see [5] ).
Here, we studied the relationship between Treg content in nonmanipulated BM transplants and aGVHD occurrence in a retrospective study of 49 consecutive HLA-matched sibling transplantations.
MATERIALS AND METHODS
Patients
Forty-nine consecutive patients transplanted grafted at the Pitié Salpêtrière Hospital between February 2000 and July 2008, with BM from HLA-matched sibling donors, were included in this single center retrospective study. Written informed consent was obtained from all donors prior to sampling. The institutional review board ''Ile-de-France IX'' reviewed and approved the study.
Acute GVHD (grade II to IV) defined according to published criteria [6] , has occurred in 65% (32 of 49) of the patients. All patients received a myeloablative conditioning regimen (total body irradiation [TBI] and high-dose cyclophosphamide or high-dose cyclophosphamide plus busulfan) and GVHD prophylaxis with a short course of methotrexate (15 mg/m 2 on day 1, 10 mg/m 2 on day 3, and 10 mg/m 2 on day 6) and cyclosporine. They all engrafted successfully. Grade II-IV aGVHD were treated with corticosteroids (n 5 32) with anti-rIL2 (n 5 5) or mycophenolate mofetil (n 5 3) or both (n 5 1).
BM Analysis
The concentration (cells/mL) of T lymphocytes was established from fresh bone marrow samples with a 3-color flow cytometry using BD Multitest (CD3/ CD19/CD45) with Trucount tubes containing fluorescents beads as internal standard (BD Biosciences, Mountain View, CA). Treg analysis was performed on BM sample aliquots after thawing. No difference before and after cryopreservation/thawing was observed ( Figure S1 ). Intranuclear forkhead box P3 (FoxP3) labeling was performed after CD3 (Clone UCHT1 Beckman Coulter, Villepinte, France), CD4 (Clone SFC12T4D11) and CD25 (Clone M-A251; BD Biosciences) membrane staining using antihuman Foxp3 kit (PCH101 clone, eBioscience, San Diego, CA), with rat IGg2a isotypic control. Cells acquisition and analysis was performed on a FacsCalibur cytometer using CellQuest software (BD Biosciences).
Statistical Analysis
A Mann-Whitney test was used to compare clinical and biologic characteristics in patients with aGVHD versus patients who did not experience aGVHD. Univariate and multivariate Cox model regression analysis of time to aGVHD was used to evaluate the influence of each candidate prognostic factor on the risk of aGVHD. Data were analyzed using JMP software (version 8.0; SAS Institute Inc., Cary, NC), and statistical threshold for significance set at P (a 2-tailed) \.05. Sample size was calculated based on the 3 previous studies and powered to detect a similar difference [6] [7] [8] . We calculated that with our cohort (aGVHD, n 5 32; noaGVHD, n 5 17), the power was .80% (at p (a 1-tailed) \.05) to detect a 60% increase in the bone marrow graft Treg content in the no-aGVHD group versus aGVHD 1 (by the t-test) [6] , or to detect a 35% increase in aGVHD-free survival in high-Treg versus low-Treg group (by the log-rank test) [7, 8] .
RESULTS AND DISCUSSION
Following BMT, 32 (65%) patients developed an aGVHD (grade II, n 5 24, grade III-IV, n 5 8). Cox regression analysis showed a trends in increase in aGVHD risk with increasing CD3 and Foxp3 1 , respectively). A multivariate Cox model analysis showed that Treg content was not an independent predictor (CD25, P 5 .18; CD3 P 5 .01) of aGVHD even following adjustment for CD3 content. We thus conclude that, in contrast to previous observations in PBSC transplantation, our results do not support the usefulness of assessing allogeneic BM Treg content to predict aGVHD. However, given the limited dimension of these cohorts we cannot rule out an effect of smaller magnitude. As a consequence, our conclusions probably need to be confirmed in a larger sample.
Three previous studies [7] [8] [9] showed that a high level of Treg in donor peripheral blood was associated with reduced cumulative incidence of aGVHD in cohorts of 22, 63, and 34 patients, respectively. In 1 of these studies Treg measurement was performed before granulocyte-colony stimulating factor (G-CSF) administration [7] , whereas it was performed after for the 2 remaining. These results were observed both in related and unrelated PBSC myeloablative transplantations but not with reduced-intensity conditioning (RIC). In addition, these studies focused on absolute numbers of Treg but not on the percentage of Treg among CD3 1 
or CD4
1 T cells within graft, which is a determinant parameter regarding the suppressive effect of Treg [10] .
The source of HSC (PBSC versus BM) may also impact the Treg content as recently observed by Blache et al. [11] , and consequently, relationship between the Treg content of the transplant and the risk of aGVHD [12, 13] . In our study involving BM only, patients received about 10-fold fewer CD3 1 T cells compared with studies performed with PBSC [8, 9] . Despite a similar incidence of aGVHD observed in these 2 settings, it remains possible though highly speculative, that Treg variation may have more relevance when increased numbers of T cells are injected. In addition, CD3 and Treg should have a dual and opposite effect on the risk of aGVHD, although both are linearly related as shown by the high correlation in our study. Hence, the modeling of the effect of the variation of these 2 parameters on the risk of aGVHD is likely to be nonlinear. Indeed, in our study as in Pabst et al. [8, 9] , in multivariate analysis, Treg is not an independent predictor of the risk of aGVHD. Finally, G-CSF treatment may have modified the Treg content and/or the rate of GVHD occurrence. Unfortunately, the impact of G-CSF on T cells is not entirely understood [11, 14, 15] . Our study has the advantage that neither donors nor recipients were treated with G-CSF, thereby avoiding a possible confounding factor.
The hypothesis that the Treg graft content may be related to GVHD occurrence originated from mouse experiments. Notably, accelerated GVHD was observed only when the transplant was fully Treg depleted [2, 3] , and protection against GVHD was only achieved when using Treg at the very high ratio of 1:1 Treg to conventional CD4 1 T cell [2, 3, [16] [17] [18] [19] . Despite the substantial variation in Treg concentration among donors (near 1 log in our study), the mean ratio of Treg to conventional CD4 1 T cells (1:35 in BM samples) is far lower than the 1:1 ratio required for a therapeutic effect in murine models. Consequently, the impact of variations of Treg content that we observed in nonmanipulated human transplants may be of lesser significance. However, in the absence of correlation in this study and based on previous studies in mice, it may be worthwhile to manipulate Treg to a greater degree than that which occurs naturally. aGVHD may be attenuated or prevented by increasing the ratio of Treg in the transplant. Alternatively, Treg depletion may improve the graft-versus-tumor (GVT) effect of donor lymphocytes [20] . We have recently successfully tested this approach in a clinical trial which demonstrates that Treg depletion is a safe approach that induces GVHD and antitumoral effect in patients not responding to a classical donor lymphocyte infusion [21] .
